In recently reported clinical trials for CD7 CAR-T cells, the rates of severe advert events (grade ≥ 3) within 1 month post-infusion were as follows: CRS (0%-66.7%), ICANS (0%-14.3%), GvHD (0%-14.3%), anemia (0%-91.7%), neutropenia (85.7%-100%), and thrombocytopenia (57.1%-95%) [8, 10, 11, 13, 14, 23]. This evidence concerns the gene CD7 and graft versus host disease.